Literature DB >> 1671130

Fatal systemic lupus erythematosus in patient taking oral iron chelator L1.

J Mehta, S Singhal, R Revankar, A Walvalkar, A Chablani, B C Mehta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1671130     DOI： 10.1016/0140-6736(91)90906-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

Authors:  J A Barman Balfour; R H Foster
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 2.  Deferiprone-related arthropathy of the knee in a thalassemic patient: report of a case and review of the literature.

Authors:  Efthimia Vlachaki; Konstantinos Tselios; Vasilios Perifanis; Ioanna Tsatra; Ioannis Tsayas
Journal:  Clin Rheumatol       Date:  2008-07-29       Impact factor: 2.980

Review 3.  Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).

Authors:  M B Agarwal
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 4.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 5.  A risk-benefit assessment of iron-chelation therapy.

Authors:  J B Porter
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.228
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.